Novel experimental agent is highly active in CLL patients, interim study shows
Monday, June 6, 2011 - 09:00
in Health & Medicine
An interim analysis of a phase II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated both in patients who are undergoing treatment for the first time and those who have relapsed and are resistant to other therapy.